Drug Ther Bull. 2011 Sep;49(9):102-5. doi: 10.1136/dtb.2011.02.0053.
Helicobacter pylori eradication therapy helps to prevent recurrence of, and re-bleeding from, gastric and duodenal ulcers. It also causes regression of most localised gastric mucosa-associated lymphoid-tissue (MALT) lymphomas. Standard triple therapy (comprising a proton pump inhibitor [PPI] plus two antibacterials) has been used routinely to eradicate H. pylori. However, the effectiveness of this type of regimen has declined over time, mainly due to antibacterial resistance. Consequently, other regimens are being used, and these include sequential therapy (e.g. a PPI plus amoxicillin, followed by a PPI plus two other antibacterials). Here we assess the efficacy and safety of sequential H. pylori eradication therapy.
幽门螺杆菌根除治疗有助于预防胃和十二指肠溃疡的复发及再出血。它还能使大多数局限性胃黏膜相关淋巴组织（MALT）淋巴瘤消退。标准三联疗法（包含一种质子泵抑制剂[PPI]加两种抗菌药物）一直被常规用于根除幽门螺杆菌。然而，随着时间推移，这类疗法的有效性有所下降，主要原因是细菌耐药性。因此，正在使用其他疗法，其中包括序贯疗法（例如一种PPI加阿莫西林，随后是一种PPI加另外两种抗菌药物）。在此，我们评估幽门螺杆菌根除序贯疗法的疗效和安全性。
